AstraZeneca’s jab had bumpy developments in the EU, how did it work? | World News

The EU vaccination drive was bumpy, especially the Oxford / AstraZeneca jab deployment.

In November, the European Commission celebrated the plan for a common approach and announced the creation of a “health union” with a purchase agreement. At least 300 million times From UK and Swedish pharmaceutical companies.

The deal had the option of purchasing an additional 100 million doses for 450 million citizens.

But four months later, Block programs suffer from shortages and delays, And prompted a very public and very bitter line with pharmaceutical companies.

Then it brought almost a nuclear option-triggered Article 16 of the Northern Ireland Protocol before the Commission peaked again on Thursday. Blocked shipping Vaccines for Australia

So how did you get here?

The shortage was announced on January 22nd

The European Medicines Agency (EMA) approved the use of AstraZeneca jab on January 29, but the problem had already begun.

Just a week ago, the company notified Brussels that it had a 60% shortage due to production defects in the European supply chain.

The EU expects 31 million doses by the end of March instead of the agreed 80 million doses.

The drive got off to a bad start, coupled with a temporary shortage of Pfizer / BioNTech vaccines.

Effectiveness was questioned in a German report on January 25

The German newspaper Handelsblatt has published a report suggesting that the effectiveness of AstraZeneca jabs can be reduced to 8% in ages 65 and older.

The claim was countered by the German Ministry of Public Health, AstraZeneca and the University of Oxford, stating that the claim was “unfounded.”

January 28, Germany advises banning use over 65 years old

The night before the EMA approved the jab, German health officials said the vaccine should not be given to the next person. People over 65Said that there was a lack of data on this age group.

France, Greece, Denmark, the Netherlands, Sweden, Poland and Austria eventually followed with the same restrictions.

Italy initially restricted jabs to under 55, but at the end of February raised jabs to adults up to 65.

Belgium and Spain limit it to under 55 years old.

Use Chrome Browser for a more accessible video player

Deployment of COVID vaccines in the EU slowed due to skepticism about UK vaccine production

January 28, EU orders inspection at AstraZeneca’s site

A dispute arose days after the shortfall was announced as EU authorities requested AstraZeneca to limit the expected reductions.

The Commission also threatened that Brock would impose strict export controls to ensure a fair share of the vaccine, and later provided a clause in the contract that doses would be supplied by two UK-based plants. I pointed out.

However, Pascal Soriot, CEO of AstraZeneca, France, added that the contract included a best-effort clause and said delivery schedules were not agreed.

He said the UK contract was also signed three months before Brussels, stipulating that vaccines manufactured in the UK should be supplied to the UK first.

Currently, 1 in 7 people have antibodies, and the number is increasing thanks to the vaccine.
Brussels hinted that there was a contract breach related to AstraZeneca

In response, the EU has hinted that Mr. Soliot’s disclosure of this information (which is said to be confidential) could be a breach of contract.

However, in addition to these busy days, on January 28, the EU ordered authorities to inspect the AstraZeneca facility in Seneffe, Belgium, to confirm that there was a supply problem.

On January 29th, the AstraZeneca jab was approved. EU publishes its contract

EMA approved the use of AstraZeneca on January 29 for all adults 18 years and older, despite conflicting recommendations from Germany.

After that, French President Emmanuel Macron further weakened his confidence and Jab said “no semi-effect”..

It was also the day Brussels released a heavily edited contract. But this seemed to create more questions than I answered.

French President Emmanuel Macron makes a gesture on February 18, 2021 at a video conference at the Elysee Presidential Palace in Paris, France, to show the acceleration of the national cybersecurity strategy. LudovicMarin / Pool via REUTERS
Emmanuel Macron said in January that the jab thought it was “semi-ineffective.”

January 29, EU moves to trigger NI protocol

The procurement line quickly reached its first peak when the commission began to move. Invoking Article 16 of the Northern Ireland Protocol To prevent the vaccine from entering the UK.

You would have seen a check done on the border between the Republic and Northern Ireland.

London, Belfast and Dublin have widely condemned the move-and it eventually resulted in the Commission making a quick U-turn.

From February to March, it was reported that the uptake was low.

The bad reputation in the early weeks seems to have had a knock-on effect on AstraZeneca in Germany, as it was reported that jabs were taken up slowly.

Meanwhile, German Vaccine Standing Committee (STIKO) Chairman Thomas Mertens said, “The whole thing didn’t work for some reason,” and claimed that the vaccine was “very good.”

He told broadcaster ZDF: “We have never criticized the vaccine, just saying that the data for people over the age of 65 are bad or inadequate.”

Use Chrome Browser for a more accessible video player

Northern Ireland Protocol becomes “collateral damage”

March 4th, U-turn to enable recommendations for ages 65 and up

Later Germany Overturned that recommendation Only for limiting jabs to under 65, France made a partial U-turn, granting AstraZeneca vaccine to people aged 65 to 74 in existing health.

This is the latest data released by the UK Public Health Service (PHE) based on the UK vaccine deployment for patients over 70 years of age four weeks after the first jab, from 60-73% to 57-61 of Pfizer. After showing protection against symptomatological COVID in the% range. / BioNTech vaccine.

EU blocks shipments to Australia on March 4

Because AstraZeneca failed to fulfill its contractual promise Italy and European Commission blocked request Exports 250,000 batches from the Anagni plant near Rome.

The move came under a new export control system that was enacted on January 30 and was first used by Member States.

In a statement, the Italian Ministry of Foreign Affairs cites reasons such as the low number of COVID cases and the lack of vaccines in Europe, which makes Australia considered “not vulnerable”.

It is understood that doses are redistributed within the EU, where about 8% of the population is vaccinated, compared to more than 30% in the UK.

AstraZeneca’s jab had bumpy developments in the EU, how did it work? | World News

Source link AstraZeneca’s jab had bumpy developments in the EU, how did it work? | World News

Back to top button